Trial Profile
A feasibility study of EdoXaban for the Cancer-Associated asymptomatic Venous thromboEmbolism in Japanese gastrointestinal cancer patients receiving chemotherapy. (ExCAVE study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Acronyms ExCAVE study
- 16 Dec 2022 Results assessing the feasibility of edoxaban without initial heparin usage for asymptomatic cancer-associated thrombosis (CAT) in Japanese patients with gastrointestinal cancer (GIC) at high risk of bleeding, published in the BMC Cancer.
- 15 Nov 2021 Status changed from recruiting to completed.
- 17 Feb 2018 Status changed from not yet recruiting to recruiting.